Previous 10 | Next 10 |
2024-05-14 16:14:54 ET More on BioCardia BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript BioCardia spikes after Medicare coverage for cell therapy trial Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Fi...
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report o...
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the the three months ended ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP&...
SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced completion of enrollment and collection of the primary endpoint results of t...
2024-03-27 20:00:12 ET BioCardia, Inc. (BCDA) Q4 2023 Results Conference Call March 27, 2024 04:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and Chief Executive Officer David McClung - Chief Financial Officer Pres...
2024-03-27 16:17:20 ET More on BioCardia BioCardia spikes after Medicare coverage for cell therapy trial Seeking Alpha’s Quant Rating on BioCardia Historical earnings data for BioCardia Financial information for BioCardia Read the full articl...
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its ann...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
News, Short Squeeze, Breakout and More Instantly...
SUNNYVALE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Unites States Patent Office has granted Patent No: ...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...